PneumoWave
Suites 3 and 4 Second Floor Maxim 3 Maxim Office Park Parklands Ave, Holytown, North Lanarkshire, ML1 4WQ, United Kingdom
Overview
PneumoWave is advancing a wearable biosensor platform to remotely diagnose and monitor potentially fatal respiratory changes in high‑risk patient groups. Led by CEO Dr Bruce Henderson, the device alerts carers and emergency medical services when dangerous respiratory events are detected. The company raised £7.5M in Series A funding to enable clinical validation and regulatory submission of its platform. PneumoWave aims to reduce the socioeconomic impact of drug overdose, which the article identifies as the leading cause of accidental death in many developed countries. Its technology is being developed as part of an international research programme with the University of Dundee, University of Glasgow, King’s College London, and the NRCH and Department of Health in Victoria, Australia.
- Total raised
- $9M
- Funding rounds
- 1
- Latest round
- Series A
- Latest activity
- Jan 2023
Industries
- Artificial Intelligence (AI)
- Health Care
- Health Diagnostics
- Machine Learning
- Medical Device
- Sensor
- Therapeutics
Recent funding
Series A
Jan 2023
$9M